Board of Directors

Claes Post

Claes Post

Chairman, Pharm Dr, Professor

Claes Post has a Master of Pharmacy from Uppsala University, Pharm Dr from Linköping University, Associate Professor in Neuropharmacology and Anaesthesiology from Uppsala University, Professor (Adjunct) in Neuropharmacology at Linköping University. Between 1981 and 1994 he was Preclinical Vice President at Astra Pain Control and Astra Draco, then between 1994 and 1997 he was Senior Vice President Preclinical and Clinical CNS Drug Discovery and Development, as well as Medical Director CNS at Pharmacia in Milan, Italy. He has been CEO of several start-up companies in the pharmaceutical fields, been engaged in university-based technology transfer, and Investment Manager at ALMI INVEST AB. He is a Board member of four Life science companies. Claes has published more than 140 articles in peer-review scientific journals and has been mentor and supervisor of MD and PhD students.

Board member since 2017.

Holdings in AroCell: Nil shares.
Warrants in AroCell: 100 000.

Independent in relation to the company and its management and in relation to major shareholders.

Staffan Eriksson

Staffan Eriksson

MD, PhD, Professor

Staffan Eriksson has more than 35 years’ experience in medical biochemistry and cell biology with a PhD and an MD from the Karolinska Institute. He was appointed Professor in Medical and Physiological Chemistry at The Swedish University of Agricultural Sciences, Uppsala, in 1992. He has published more than 200 publications in peer-reviewed journals and supervised 15 doctoral students. Staffan is a leading scientist in the area of structure and function of Thymidine Kinase 1 with more than 100 publications during the last 10 years.

Staffan is one of the founders of AroCell and has served as CSO and Board Member of AroCell since 2003.

Holdings in AroCell: 1 108 630 shares.
Warrants in AroCell: 100 000.

Independent in relation to the company and its management and in relation to major shareholders.

Agneta Franksson

Agneta Franksson

MBA, M Sc

Agneta Franksson holds an MBA from Uppsala University and a Master of Science degree from the Royal institute of Technology in Stockholm. Agneta has experience from two CEO positions, Vita Nova Ventures AB (Publ) (a CRO company) and Falck Ambulans AB (healthcare services) and more than 25 years’ experience from research, clinical trials, product/service development, and international sales and marketing.

Since 2006 she has run her own management consulting firm focusing on analytic work, developing road maps, strategic plans, project managements, brand, profile, value work, and implementation of market access strategies. Agneta has served on several boards during the last 12 years. Today she is a member of the board of Blekinge Institute of Technology and serves as the Chairman of the Board of Directors of Specialplast Wensbo AB and HoofStep AB. She received the national prize “Supergasell 2016” (Dagens Industri).

Board member since 2017

Holdings in AroCell: Nil shares.

Independent in relation to the company and its management and in relation to major shareholders.

Karin Eriksson-Widblom

Karin Eriksson-Widblom

M Sc

Karin Eriksson-Widblom has worked as a Sales and Marketing Director at Fujirebio Diagnostics AB for several years and has held several other positions at, among others, EniChem and Nolato Medical. Karin has therefore extensive experience in marketing and sales of biomarkers focused on oncology.

Board member since 2019

Warrants in AroCell: 100 000.

Independent in relation to the company and its management and in relation to major shareholders.

Gunnar Steineck

Gunnar Steineck

PhD, Professor

Gunnar Steineck has more than 30 years’ experience with research in the medical field. After studies in Mathematics, Statistics, and Medicine at Uppsala University he received training in oncology and radiotherapy at Karolinska University Hospital and became a specialist in 1990. After a PhD exam (1990), Gunnar became an Associate Professor (1992) and subsequently did Post-doctoral studies at Memorial Sloan-Kettering Cancer Center in New York. In 2002, he was appointed Professor at Karolinska Institute and in 2004 he accepted a Professor’s Chair in Clinical Cancer Epidemiology at Gothenburg University. The focus of the present research program is cure from cancer with restored health. Gunnar has more than 300 articles published inpeer-reviewed journals covering studies of markers, randomized investigations and large-scale observational data collections.

Professor Steineck’s strengths include a broad overview of the medical field together with thorough methodological insights concerning clinical research. He has given courses in clinical epidemiology and biostatistics for 25 years and is currently Head of the Clinical Research School at Sahlgrenska Academy.

Board member since 2017

Holdings in AroCell: Nil shares.
Warrants in AroCell: 100 000.

Independent in relation to the company and its management and in relation to major shareholders.